Hengrui Medicine's Carrelizumab was approved for the world's first first-line nasopharyngeal cancer indication

Carrelizumab has another good news
.

Recently, the PD-1 inhibitor Carrelizumab (Erica®) independently developed by Hengrui Medicine has officially obtained the "Drug Registration Certificate" approved and issued by the National Medical Products Administration (NMPA), approving Carrelizumab Monoclonal antibody combined with cisplatin and gemcitabine is used for the first-line treatment of patients with locally recurring or metastatic nasopharyngeal carcinoma

Significantly prolong the progression-free survival of patients with advanced nasopharyngeal carcinoma

Significantly prolong the progression-free survival of patients with advanced nasopharyngeal carcinoma

Nasopharyngeal carcinoma is one of the most common tumors in China, and 50% of nasopharyngeal carcinomas in the world occur in China
.

As nasopharyngeal carcinoma has obvious geographical distribution characteristics, the incidence of nasopharyngeal carcinoma is relatively high in southern China, among which Guangdong Province has the highest incidence of nasopharyngeal carcinoma

The approval of carrelizumab for nasopharyngeal carcinoma is based on the CAPTAIN-1ST study led by Professor Zhang Li from the Cancer Center of Sun Yat-sen University
.

The CAPTAIN-1ST study is a randomized, double-blind, randomized, double-blind, randomized, double-blind, randomized, double-blind, randomized, double-blind, randomized, double-blind, assessing the effectiveness and safety of carrelizumab combined with cisplatin and gemcitabine compared to placebo combined with cisplatin and gemcitabine in the first-line treatment of locally recurring or metastatic nasopharyngeal carcinoma A placebo-controlled, multi-center phase III clinical study.

A total of 263 subjects were enrolled in this study, all patients with late recurrence or metastasis, all with distant metastasis, were randomly enrolled according to 1:1, and the enrolled subjects received carrelizumab.
200mg or placebo combined with cisplatin and gemcitabine (GP), combined treatment for 4-6 cycles, then receive carrelizumab or placebo for maintenance treatment until the disease progresses, toxicity is intolerable or other conditions that require termination of treatment
.

The results of the analysis during the study period showed that carrelizumab combined with GP can significantly prolong the progression-free survival of patients and reduce the risk of disease progression or death by 46%

Carrelizumab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurring or metastatic nasopharyngeal carcinoma is expected to become the new standard treatment for locally advanced recurrent/metastatic advanced nasopharyngeal carcinoma, which will enable more advanced noses Patients with pharyngeal cancer benefit
.

Carrelizumab shines at ASCO annual meeting

Carrelizumab shines at ASCO annual meeting

Prior to this, Carrelizumab had been approved by the NMPA in May 2019 for the treatment of patients with relapsed or refractory classic Hodgkin’s lymphoma who had undergone at least second-line chemotherapy; obtained in March 2020 NMPA is approved for the treatment of patients with advanced hepatocellular carcinoma who have received sorafenib treatment and/or oxaliplatin-containing system chemotherapy; in June 2020, it was approved by NMPA in combination with pemetrexed and carboplatin for epidermal growth First-line treatment of non-squamous non-small cell lung cancer (NSCLC) that is negative for factor receptor (EGFR) gene mutations and anaplastic lymphoma kinase (ALK) negative, unresectable locally advanced or metastatic; obtained in June 2020 NMPA is approved for the treatment of locally advanced or metastatic esophageal squamous cell carcinoma patients with disease progression or intolerance after previous first-line chemotherapy; NMPA approved in April 2021 for the treatment of disease progression or after previous second-line chemotherapy or above Treatment of intolerable advanced nasopharyngeal carcinoma patients
.

With the approval of the first-line indications for nasopharyngeal carcinoma, carrelizumab has 6 major indications and is still the domestic immune checkpoint inhibitor covering the most types of indications

Since the advent of carrelizumab, clinical research results have been on the stage of international academic conferences many times, and clinical research in the fields of nasopharyngeal cancer, liver cancer, esophageal cancer, lung cancer and other fields have reached the top of the Lancet series of journals.
, Has been widely recognized in the oncology field at home and abroad
.

At the just-concluded 2021ASCO annual meeting, Hengrui Medicine has a total of 64 studies selected, and carrelizumab is more than half of the country, and a total of 38 studies have been selected (3 oral, 14 e-poster, 21 online abstract) , Across 11 cancer types including breast cancer, gastrointestinal tumor, lung cancer, pancreatic cancer, etc.

Benefiting people's livelihood: 4 major indications have entered medical insurance

Benefiting people's livelihood: 4 major indications have entered medical insurance

For immunotherapeutic drugs, in addition to expanding indications and overcoming technical difficulties, lowering prices for medical insurance on the basis of excellent curative effects will also help make innovative drugs better benefit the people's livelihood
.

At the end of December 2020, Karelizumab was successfully included in the new version of the National Medical Insurance List.

As the leader of national medicine innovation, Hengrui Medicine has been adhering to the original research for many years, and is committed to providing good "weapons" for Chinese doctors and providing more treatment opportunities for Chinese patients
.

As an innovative drug originally developed in China, Carrelizumab has always focused on the high incidence of malignant tumors in China.

Subsequent research and development of karelizumab not only focuses on the combination of existing indications and cancer types, but also focuses on the expansion of indications for other cancer types.
It is expected that karelizumab can benefit more cancer patients in the future.
Make greater contributions to the global fight against cancer
.